ReviewBiomolecules2021
Cardiorenal Syndrome: New Pathways and Novel Biomarkers.
Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 60 citations in OpenAlex.
- Combined podocyte, fibrotic and echocardiographic correlates of an operationally defined subclinical cardiorenal phenotype in chronic kidney disease: an exploratory study.Renal failure · 2026Observational
- Beyond Creatinine: Novel Renal Biomarkers at the Interface of Kidney Injury and Cardiovascular Risk.Biomedicines · 2026Review
- The Cardiovascular Burden of Diabetes: Risk Factors, Clinical Phenotypes, and Personalized Cardiometabolic Management.Journal of clinical medicine · 2026Review
- Evaluation of Urinary Tubular Biomarkers in Dogs with Myxomatous Mitral Valve Disease Across ACVIM Stages.Veterinary sciences · 2026Article
- Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management.Frontiers in cardiovascular medicine · 2026Review
- Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i.Renal failure · 2025Review
- Early prediction of sepsis-induced cardiorenal syndrome: superiority of myoglobin over troponin I.Renal failure · 2025Article
- Unraveling Non-coding RNAs and dysregulation of TGF-β signalling in cardiorenal syndrome, a focused review for molecular and clinical applications.Molecular biology reports · 2025Review
- Organ-system-based subclassification of preeclampsia using machine learning predicts pregnancy outcomes.BMC pregnancy and childbirth · 2025Article
- Roles of microRNAs in cardiorenal syndrome.Molecular and cellular biochemistry · 2025Review
- Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker of Acute Kidney Injury (AKI) in Dogs with Congestive Heart Failure (CHF) Due to Myxomatous Mitral Valve Disease (MMVD).Animals : an open access journal from MDPI · 2025Article
- Heart Failure-Focus on Kidney Replacement Therapy: Why, When, and How?International journal of molecular sciences · 2025Review
- VExUS Protocol Along Cardiorenal Syndrome: An Updated Review.Journal of clinical medicine · 2025Review
- The Role of NT-proBNP Levels in the Diagnosis of Hypertensive Heart Disease.Diagnostics (Basel, Switzerland) · 2025Review
- The Role of Oral Biomarkers in the Assessment of Noncommunicable Diseases.Diagnostics (Basel, Switzerland) · 2024Review
- Recent Progress in Molecular Probes for Imaging of Acute Kidney Injury.Chemical & biomedical imaging · 2024Review
- Review
- Cardiorenal Syndromes and Their Role in Water and Sodium Homeostasis.Physiological research · 2024Review
- Venous Doppler flow patterns, venous congestion, heart disease and renal dysfunction: A complex liaison.World journal of cardiology · 2024Article
- A Nomogram Incorporating Inflammation and Nutrition Indexes for Predicting Outcomes in Patients with Acute Coronary Syndrome and Chronic Kidney Disease.Journal of inflammation research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiorenal syndrome (CRS) is a multi-organ disease characterized by the complex interaction between heart and kidney during acute or chronic injury. The pathogenesis of CRS involves metabolic, hemodynamic, neurohormonal, and inflammatory mechanisms, and atherosclerotic degeneration. In the process of better understanding the bi-directional pathophysiological aspects of CRS, the need to find precise and easy-to-use markers has also evolved. Based on the new pathophysiological standpoints and an overall vision of the CRS, the literature on renal, cardiac, metabolic, oxidative, and vascular circulating biomarkers was evaluated. Though the effectiveness of different extensively applied biomarkers remains controversial, evidence for several indicators, particularly when combined, has increased in recent years. From new aspects of classic biomarkers to microRNAs, this review aimed at a 360-degree analysis of the pathways that balance the kidney and the heart physiologies. In this delicate system, different markers and their combination can shed light on the diagnosis, risk, and prognosis of CRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.